Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2008
04/17/2008US20080091020 Polymorphic forms of ziprasidone HCI and processes for their preparation
04/17/2008US20080091019 Crystalline form having X-Ray powder diffraction pattern with peaks at 9.4, 13.7, 14.5, 14.9, 18.1, 20.2, 22.8+-0.2 degrees 2 theta; reacting salt of ziprasidone with alkaline agent and precipitating
04/17/2008US20080091018 Polymorphic form B2 of ziprasidone base
04/17/2008US20080091017 Polymorphic form B2 of ziprasidone base
04/17/2008US20080091010 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; antiviral and antitumor agents
04/17/2008US20080091006 Nitrate ester cyclodextrin complexes
04/17/2008US20080090996 Thrombopoietin mimetics
04/17/2008US20080090916 2-Amino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid, aka gamma-L-glutamyl-1R,2S-methoxamine; prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form; transdermal administration; coupling methoxamine with glutamic acid alcohol
04/17/2008US20080090915 Method for preventing or attenuating anthracycline-induced cardiotoxicity
04/17/2008US20080090914 Staining Composition For Staining An Ophthalmic Membrane
04/17/2008US20080090913 Sphingolipid-Derived Phamaceutical Compositions
04/17/2008US20080090912 Compositions containing prodrugs of florfenicol and methods of use
04/17/2008US20080090911 Storage stability; ethyl laurate and guar gum; alcohol free; topical administration; sexual disorders
04/17/2008US20080090910 Methods for treatment of nocturia
04/17/2008US20080090909 negative regulator of cell growth factor receptor; pelorol (benzo(a)fluorene) related compounds from marine sponge species; antiinflammatory, antitumor agent, immunostimulant; control gene expression, differentiation, metabolism, phospholipid signaling pathway, signal tansduction
04/17/2008US20080090908 Transformating growth factors; mucor/borage oils; multiple sclerosis
04/17/2008US20080090907 Crystal Comprising (2R)-2-Propyloctanoic Acid and Amine
04/17/2008US20080090906 Dietetics; cancer
04/17/2008US20080090905 Antidiabetic agents; insulin resistance; dyslipidemias; dietetics
04/17/2008US20080090904 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
04/17/2008US20080090903 Improved stability via dibasic calcium phosphate dihydrate excipient; tablets; nervous system disorders
04/17/2008US20080090902 Improved stability via dibasic calcium phosphate dihydrate excipient; tablets; nervous system disorders
04/17/2008US20080090901 Process to obtain dibenzylbutyrolactonic lignans, process to obtain synthetic derivatives from lignans bearing anti-chagas chemoprophylactic and therapeutical activities
04/17/2008US20080090900 Antibiotic bushrin
04/17/2008US20080090899 Application of water and organic solvent soluble ivermectin for topical and oral use
04/17/2008US20080090898 Boosting immunity
04/17/2008US20080090897 Neurodegenerative diseases such as Alzheimer's Disease, multiple sclerosis, Huntington's Disease, or Parkinson's Disease, AIDS related dementia, Amyotrophic Lateral Sclerosis; use of compounds derived from a 4,4,8-trimethyl-17-furanylsteroid skeleton, tetranortriterpenoids
04/17/2008US20080090896 Strontium-Based Treatment Of Otosclerosis
04/17/2008US20080090895 Novel Pharmaceutical Composition And Their Uses Thereof For Controlling The Different Forms Of Addiction To Drugs
04/17/2008US20080090894 Transdermal migraine therapy
04/17/2008US20080090893 Use of indoline derivatives such as silodosin to prevent transition to surgical therapy of benign prostatic hyperplasia
04/17/2008US20080090892 Amorphous asenapine and processes for preparing same
04/17/2008US20080090891 Administering calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders
04/17/2008US20080090890 Substituted, bicyclic 8-pyrrolidinobenzimidazoles, methods for their production and their use as medicaments
04/17/2008US20080090889 Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use
04/17/2008US20080090888 Methods and materials for assessing prostate cancer therapies and compounds
04/17/2008US20080090887 Triazole compounds that modulate HSP90 activity
04/17/2008US20080090885 Combining water, potassium permanganate, and polar inert organic solvent to form first reaction mixture, filtering, adding losartan to form second reaction mixture, adding formaldehyde to second reaction mixture to form precipitate,filtering, acidifying to form precipitate of losartan 5-carboxylic acid
04/17/2008US20080090884 Antimicrobial [3.1.0] bicyclohexylphenyl- oxazolidinone derivatives and analogues
04/17/2008US20080090883 Hormone-dependent cancers such as breast cancer or prostate cancer; 4-aryl or heteroaryl-substituted 3,3-dioxo-3-thia-4-azatricyclo[5.2.1.02,6]dec-8-ene
04/17/2008US20080090882 Heterocyclic Carbonyl Compounds
04/17/2008US20080090881 Treatment of diabetes with thiazolidinedione and metformin
04/17/2008US20080090880 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators
04/17/2008US20080090879 Method of treatment
04/17/2008US20080090878 Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
04/17/2008US20080090877 Sulfone impurity can be removed using amine salts of 2-[(4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole when manufacturing the drug pariprazole
04/17/2008US20080090876 Diacylglycerol o-acyltransferase (DGAT); treating obesity; for example 2-(2,6-diisopropyl-4-methylphenylaminocarbonyl)-3,6-dipentyl-3,6-dihydro-2H-thiopyran
04/17/2008US20080090875 Analgesics, antipyretics, antiinflammatory agents; 4-(4-chlorophenyl)-5-(4-methanesulfonylphenyl)-1,2-dihydropyrazole-3-thione for example; cyclooxygenase-2 (COX-2) inhibitors; side effect reduction
04/17/2008US20080090874 Treatment of breakthrough pain in patients suffering from chronic low back pain
04/17/2008US20080090873 Sulfonamide derivatives
04/17/2008US20080090872 AMPA and NMDA receptor modulators; depression, epilepsy, schizophrenia, Alzheimer's, disease, learning and memory disorders, and mild cognitive impairment; 5,1',5'-trimethyl-2'-phenyl-1',2'-dihydro-2H-[3,4']bipyrazolyl-3'-one for example
04/17/2008US20080090871 Cannabimimetic indole derivatives
04/17/2008US20080090870 Use of 2-(amino-substituted piperidin-1-yl)benzimidazoles as antidiabetic agents, or to treat carbohydrate and lipid metabolic disorders; use in combination with other drugs; N-[2-(3-Aminopiperidin-1-yl)-1-(3-methylbut-2-enyl)-1H-benzimidazol-6-yl]-benzenesulfonamide or salts for example
04/17/2008US20080090869 Antidiabetic agents, carbohydrate and lipid metabolic disorders; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-[2-(3-Aminopiperidin-1-yl)-1-(3-methylbut-2-enyl)-1H-benzimidazol-6-y]-benzamide trifluoroacetic acid salt for example; use in combination with other drugs
04/17/2008US20080090868 Antidiabetic agents; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-(4-Chlorobenzyl)-2-(3-aminopiperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzimidazole-6-carboxamide hydrochloride for example; use in combination with other antidiabetic, antilipemic agents
04/17/2008US20080090867 Azole derivatives in the form of lipase and phospholipase inhibitors
04/17/2008US20080090866 Cosmetic Use of Piperidine Derivatives
04/17/2008US20080090865 Non-insulin dependent diabetes; agonists of G-protein coupled receptor 40 (GPR40); for example, 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline
04/17/2008US20080090864 Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
04/17/2008US20080090863 Melanin Concentrating Hormone (MCH) receptor antagonists; eating disorder, obesity, psychological disorders, drug addiction, diabetes, cardiovascular disorders; 2-(cyclohexyl(alkyl)amino)pyridines such as 3-chloro-4-fluoro-N-(cis-4-[(4-methoxypyridin-2-yl)amino]cyclohexyl)benzamide
04/17/2008US20080090862 Isoquinoline Derivatives as Calpain Inhibitors
04/17/2008US20080090861 Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors
04/17/2008US20080090860 Side effect reduction; 2-carboxy-4-(2-propoxy-3,5-di-tert-butylphenyl)-benzo[b]thiophene for example; syndrome X, non-insulin dependent diabetes mellitus, cancer, photoaging, acne, psoriasis, obesity, cardiovascular disease, atherosclerosis, uterine leiomyomata, inflamatory or neurodegenerative disease
04/17/2008US20080090859 For example, N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl) ethyl]-2,2-diphenylacetamide; for the diagnosis, prophylaxis and or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders
04/17/2008US20080090858 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
04/17/2008US20080090857 Statin derivatives
04/17/2008US20080090856 useful for the modulation of kinase activity of C-Abl, c-Kit, VEGFR, PDGFR, Flt-3, c-MET, HER family, Raf kinase family and disease polymorphs thereof; hyperproliferative diseases, cancer; 1-(5-(4-(1H-pyrazol-4-yl)pyrimidin-2-yloxy)-2-fluorophenyl)-3-(3-isopropyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)urea
04/17/2008US20080090855 Substituted Cyclic Urea Derivatives and the Use Thereof as Vanilloid Receptor 1 Modulators
04/17/2008US20080090854 Cxcr2 inhibitors
04/17/2008US20080090853 Methyl 2-[4-({[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl}-{[4'-(trifluoromethyl)-4-biphenylyl]methyl}amino)-1-piperidinyl]-2-methylpropanoate, or a salt thereof; preventing or treating diseases such as atherosclerosis, diabetes, rheumatoid arthritis, stroke, inflammation
04/17/2008US20080090852 Bicyclic Heteroaromatic Compounds
04/17/2008US20080090851 Bicyclic Heteroaromatic Compounds
04/17/2008US20080090850 Herpetic neuralgia topical treatment
04/17/2008US20080090849 Protein kinase inhibitors, in particular inhibitory properties for CIV1 protein; N2-(4-aminocyclohexyl)-N6-(2-aminoethyl)-1H-purine-2,6-diamine trihydrochloride; fungal diseases such as candidiases, aspergilloses, histoplasmoses and coccidoidoses; fungicidal infections
04/17/2008US20080090848 Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides
04/17/2008US20080090847 Heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
04/17/2008US20080090846 Chemokine receptor binding heterocyclic compounds
04/17/2008US20080090845 Haloalkyl-substituted pyrimidinone derivatives
04/17/2008US20080090844 Infections caused by adenovirus, cytomegalovirus, hepatitis A virus (HAV), hepatitis B virus (HBV), flaviviruses including Yellow Fever virus, herpes virus; Immunomodulators; antiviral and antitumor agents; modulation of cytokine receptors; improved oral tolerability
04/17/2008US20080090843 Pharmaceutical formulation for treatment of HBV infection comprising a compound that inhibits the activity of a Src kinase in an amount effective to inhibit HBV replication and a pharmaceutically acceptable carrier
04/17/2008US20080090842 Novel pyridyl cyanoguanidine compounds
04/17/2008US20080090841 pyrazinoylguanidine derivatives; more potent, more specific, and/or absorbed less rapidly from mucosal surfaces, and/or are less reversible, give a prolonged pharmacodynamic half-life; treating anthrax, chronic bronchitis, cystic fibrosis,chronic obstructive pulmonary disease, emphysema, pneumonia
04/17/2008US20080090840 Heterocyclic GPR40 Modulators
04/17/2008US20080090839 Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
04/17/2008US20080090838 N-Hydroxyamide Derivatives and Use Thereof
04/17/2008US20080090837 Biaryls useful as modulators of ion channels
04/17/2008US20080090836 Pyrazole Compounds Useful In The Treatment Of Inflammation
04/17/2008US20080090835 Polymorphic forms of ziprasidone HCl and processes for their preparation
04/17/2008US20080090834 Selective azole pde10a inhibitor compounds
04/17/2008US20080090833 Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha
04/17/2008US20080090832 Treating a subject with disorders involving amino acid metabolism, in particular, hyperphenylalaninemia, by administering a therapeutically effective amount of tetrahydrobiopterin (BH4) or salt thereof, wherein the BH4 is administered orally once per day; alleviates dietary restrictions
04/17/2008US20080090831 Cytotoxic agents
04/17/2008US20080090830 thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer
04/17/2008US20080090829 5-{2-[2-(4-Tert-Butyl- phenyl)-oxazol-4-yl]-ethylsulfamoyl}-2-methyl-benzoic acid methyl ester; used as peroxisome proliferator activator receptor agonist, to increase high density lipoproteins and lower LDL-cholesterol and triglycerides; treatment of atherosclerosis, cardiovascular, metabolic disorders
04/17/2008US20080090828 insecticides for soil-borne insects, such as termites and white grubs; less costly and safer to use on crops; N-{4-[(4-{bis[4-(trifluoromethyl)phenyl]methylene}piperidyl)methyl]phenyl}ethoxycarboxamide, N-oxide
04/17/2008US20080090827 Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
04/17/2008US20080090826 Muscarinic modulators
04/17/2008US20080090825 Metallo-beta-lactamase inhibitors
04/17/2008US20080090824 Novel crystalline form of linezolid
04/17/2008US20080090823 Thiadiazoles as cxc- and cc- chemokine receptor ligands